US47103J1051 - Common Stock
JANUX THERAPEUTICS INC
NASDAQ:JANX (5/17/2024, 7:07:36 PM)
After market: 47.1 0 (0%)47.1
-0.41 (-0.86%)
Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company is headquartered in San Diego, California and currently employs 60 full-time employees. The company went IPO on 2021-06-11. Its initial focus is on developing a class of T cell engagers (TCEs), and its lead product candidates are designed to target clinically validated drug targets. The company is developing a pipeline with programs targeting prostate-specific membrane antigen (PSMA), epidermal growth factor receptor (EGFR), and trophoblast cell surface antigen 2 (TROP2). Its pipeline includes PSMA-TRACTr, EGFR-TRACTr, and TROP2-TRACTr. PSMA-TRACTr is designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. Its EGFR-TRACTr is designed to target EGFR. TROP2-TRACTr is designed to target TROP2, a clinically validated anti-tumor target. Its TRACIr program targets PD-L1xCD28.
JANUX THERAPEUTICS INC
10955 Vista Sorrento Parkway, Suite 200
San Diego CALIFORNIA
P: 18587514493
CEO: David Campbell
Employees: 60
Website: https://www.januxrx.com/
/CNW/ -- USA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the...
/PRNewswire/ -- In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of...
JANX stock results show that Janux Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Janux Therapeutics (NASDAQ:JANX) just reported results for the first quarter of...
Janux Therapeutics (NASDAQ: JANX) stock price has gone vertical this year, making it one of the top-performing biotech companies in Wall Street. It jumped to a high of $61 on Monday about 975% above the lowest point in 2023, giving it a market cap of over $2.45 billion. Analysts are optimistic about Janux Janux Therapeutics […]
Here you can normally see the latest stock twits on JANX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: